Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: To investigate the efficacy and safety of tocilizumab (TCZ) humanized anti-interleukin-6 receptor monoclonal antibody, in Korean patients with active rheumatoid arthritis (RA) refractory to conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX). Methods: The main study was a 24-week, randomized, double-blind, controlled trial that was followed by a 48-week, open-labeled, extension phase. TCZ (8 mg/kg) or placebo was intravenously administered every 4 weeks. Results: Those treated with TCZ showed more favorable outcomes in terms of 20% according to the American College of Rheumatology response criteria (ACR20) and ACR50 responses, individual parameters of ACR core set, disease activity score in 28 joints (DAS28) remission, and European League Against Rheumatism (EULAR) response at week 24. These improvements were maintained or increased during the extension period. DAS28 remission at week 72 was associated with EULAR good response at week 12. The patients who experienced any adverse event (AE) were more frequent in the TCZ group compared to the placebo group. Most AEs were mild or moderate in intensity, although TCZ therapy had possible AEs including serious infection, abnormal liver function, and atherogenic lipid profile. Conclusions: TCZ infusion add-on is highly efficacious and well-tolerated in Korean patients with active RA refractory to conventional DMARDs including MTX. EULAR good response at week 12 could predict DAS28 remission at week 72.
Abstract
Background/Aims: To investigate the efficacy and safety of tocilizumab (TCZ) humanized anti-interleukin-6 receptor monoclonal antibody, in Korean patients with active rheumatoid arthritis (RA) refractory to conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX). Methods: The main study was a 24-week, randomized, double-blind, controlled trial that was followed by a 48-week, open-labeled, extension phase. TCZ (8 mg/kg) or placebo was intravenously administered every 4 weeks. Results: Those treated with TCZ showed more favorable outcomes in terms of 20% according to the American College of Rheumatology response criteria (ACR20) and ACR50 responses, individual parameters of ACR core set, disease activity score in 28 joints (DAS28) remission, and European League Against Rheumatism (EULAR) response at week 24. These improvements were maintained or increased during the extension period. DAS28 remission at week 72 was associated with EULAR good response at week 12. The patients who experienced any adverse event (AE) were more frequent in the TCZ group compared to the placebo group. Most AEs were mild or moderate in intensity, although TCZ therapy had possible AEs including serious infection, abnormal liver function, and atherogenic lipid profile. Conclusions: TCZ infusion add-on is highly efficacious and well-tolerated in Korean patients with active RA refractory to conventional DMARDs including MTX. EULAR good response at week 12 could predict DAS28 remission at week 72.
참고문헌 (41)
- Choy EH, "Cytokine pathways and joint inflammation in rheumatoid arthritis", N Engl J Med, 344, pp.907~916 (2001)
- Smolen JS, "New therapies for treatment of rheumatoid arthritis", Lancet, 370, pp.1861~1874 (2007)
- Desroches M, "Treatment failure with antagonists of TNF-α : mechanisms and implications for the care of patients", Eur Cytokine Netw, 21, pp.226~231 (2010)
- Kishimoto T, "Interleukin-6: discovery of a pleiotropic cytokine", Arthritis Res Ther, (8 Suppl 2), pp.S2~ (2006)
- Madhok R, "Serum interleukin 6 levels in rheumatoid arthritis : correlations with clinical and laboratory indices of disease activity", Ann Rheum Dis, 52, pp.232~234 (1993)
- Mihara M, "Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family", Int Immunopharmacol, 5, pp.1731~1740 (2005)
- Genovese MC, "Interleukin-6receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs : the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study", Arthritis Rheum, 58, pp.2968~2980 (2008)
- Nishimoto N, "Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis(the STREAM study) : evidence of safety and efficacy in a 5-year extension study", Ann Rheum Dis, 68, pp.1580~1584 (2009)
- Maini RN, "Double-blind randomized controlled clinical trial of the interleukin-6receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate", Arthritis Rheum, 54, pp.2817~2829 (2006)
- Emery P, "IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals : results from a 24-week multicenter randomised placebo-controlled trial", Ann Rheum Dis, 67, pp.1516~1523 (2008)
- Smolen JS, "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis(OPTION study) : a double-blind, placebo-controlled, randomised trial", Lancet, 371, pp.987~997 (2008)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update", Ann Rheum Dis, 73, pp.492~509 (2014)
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- Joint Committee for the Development of Korean Guidelines for Tuberculosis, "Korean Guidelines for Tuberculosis", Korea Centers for Disease Control and Prevention, ~ (2011)
- Paulus HE, "Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group", Arthritis Rheum, 33, pp.477~484 (1990)
- Prevoo ML, "Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis", Arthritis Rheum, 38, pp.44~48 (1995)
- van Gestel AM, "Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization", International League Against Rheumatism Criteria, 1996, pp.39, 34~40
- Fries JF, "Measurement of patient outcome in arthritis", Arthritis Rheum, 23, pp.137~145 (1980)
- "The WHO adverse reaction terminology: WHO-ART" (2017)[URL]
- Yazici Y, "Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs : the ROSE study", Ann Rheum Dis, 71, pp.198~205 (2012)
- Pers YM, "Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice", Rheumatology(Oxford), 53, pp.76~84 (2014)
- Kojima T, "Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice", Mod Rheumatol, 22, pp.370~375 (2012)
- Schiff MH, "Integrated safety in tocilizumab clinical trials", Arthritis Res Ther, 13, pp.R141~ (2011)
- Van der Meide PH, "Cytokines and the immune response", Biotherapy, 8, pp.243~249 (1996)
- Campbell L, "Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab : a systematic literature review and meta-analysis of randomized controlled trials", Rheumatology(Oxford), 50, pp.552~562 (2011)
- Fujiwara H, "Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment : a report of two cases", Mod Rheumatol, 19, pp.64~68 (2009)
- Nagabhushanam V, "Innate inhibition of adaptive immunity : Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma", J Immunol, 171, pp.4750~4757 (2003)
- Ogata A, "Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens", Mod Rheumatol, 20, pp.130~133 (2010)
- Akira S, "Interleukin-6 in biology and medicine", Adv Immunol, 54, pp.1~78 (1993)
- Asensi V, "In vivo interleukin-6 protects neutrophils from apoptosis in osteomyelitis", Infect Immun, 72, pp.3823~3828 (2004)
- Suwa T, "The effect of interleukin-6 on L-selectin levels on polymorphonuclear leukocytes", Am J Physiol Heart Circ Physiol, 283, pp.H879~ (2002)[DOI]
- Meune C, "Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years : a systematic review and meta-analysis of cohort studies", Rheumatology(Oxford), 48, pp.1309~1313 (2009)
- Martin-Martinez MA, "Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis : scientific evidence and expert opinion", Semin Arthritis Rheum, 44, pp.1~8 (2014)
- Robertson J, "Changes in lipid levels with inflammation and therapy in RA : a maturing paradigm", Nat Rev Rheumatol, 9, pp.513~523 (2013)
- Koike R, "Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis", Mod Rheumatol, 19, pp.351~357 (2009)
- De Rycke L, "Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis", Ann Rheum Dis, 64, pp.299~302 (2005)
- Bos WH, "Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis", J Rheumatol, 35, pp.1972~1977 (2008)
- Mikuls TR, "Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody", Arthritis Rheum, 50, pp.3776~3782 (2004)
- Epis O, "Clinical and serological response to tocilizumab in patients with rheumatoid arthritis", J Med Diagn Methods, 2, pp.127~ (2013)
- Anolik JH, "Cutting edge : anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks", J Immunol, 180, pp.688~692 (2008)
- Dougados M, "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders : 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis(ACT-RAY)", Ann Rheum Dis, 72, pp.43~50 (2013)